A detailed history of Axq Capital, LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Axq Capital, LP holds 3,144 shares of NBIX stock, worth $358,416. This represents 0.1% of its overall portfolio holdings.

Number of Shares
3,144
Previous 1,520 106.84%
Holding current value
$358,416
Previous $210 Million 106.47%
% of portfolio
0.1%
Previous 0.05%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$130.86 - $143.19 $212,516 - $232,540
1,624 Added 106.84%
3,144 $433 Million
Q1 2024

May 14, 2024

SELL
$130.4 - $143.74 $884,112 - $974,557
-6,780 Reduced 81.69%
1,520 $210 Million
Q4 2023

Feb 13, 2024

SELL
$106.07 - $132.76 $169,712 - $212,416
-1,600 Reduced 16.16%
8,300 $1.09 Billion
Q3 2023

Nov 14, 2023

BUY
$94.02 - $117.1 $930,798 - $1.16 Million
9,900 New
9,900 $1.11 Billion

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $10.9B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Axq Capital, LP Portfolio

Follow Axq Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Axq Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Axq Capital, LP with notifications on news.